(5R)-5-Hydroxytriptolide

Synonyms: PG 701; LLDT-8; 5α-Hydroxytriptolide
(5R)-5-Hydroxytriptolide (PG 701) 是一种具有口服活性且可穿透中枢神经系统的 NF-κB 和 TLR4 抑制剂,可抑制 IκB 降解、NF-κB 核转位、NO 释放及促炎细胞因子的表达,并上调 Tp53 转录以诱导 p53 介导的细胞凋亡 (apoptosis),可用于脑缺血/再灌注损伤、非小细胞肺癌脑转移及类风湿性关节炎的相关研究。
产品编号: MS-A82013 纯度: 99.67% CAS No.: 583028-68-6 分子式: C20H24O7 分子量: 376.40
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价

产品描述

(5R)-5-Hydroxytriptolide (PG 701) 是一种具有口服活性且可穿透中枢神经系统的 NF-κB 和 TLR4 抑制剂,可抑制 IκB 降解、NF-κB 核转位、NO 释放及促炎细胞因子的表达,并上调 Tp53 转录以诱导 p53 介导的细胞凋亡 (apoptosis),可用于脑缺血/再灌注损伤、非小细胞肺癌脑转移及类风湿性关节炎的相关研究。

生物实验数据

生物活性 (5R)-5-Hydroxytriptolide (PG 701) is an orally active NF-κB and TLR4 inhibitor capable of penetrating the central nervous system that inhibits IκB degradation, NF-κB nuclear translocation, NO release, and proinflammatory cytokine expression, upregulates Tp53 transcription to induce p53-mediated apoptosis, and can be used in studies related to cerebral ischemia/reperfusion injury, brain metastasis of non-small cell lung cancer, and rheumatoid arthritis.
体外研究
(In Vitro)

(5R)-5-Hydroxytriptolide (LLDT-8) (50-400 nM; 24 h) 可剂量依赖性地抑制 LPS (MS-X54539) 诱导的小鼠 BV-2 小胶质细胞 NO 生成。
(5R)-5-Hydroxytriptolide (50-150 nM; 6 h) 可呈剂量依赖性抑制小鼠 BV-2 小胶质细胞中 LPS 诱导的 iNOS、IL-1β 和 TNF-α mRNA 表达。
(5R)-5-Hydroxytriptolide (50-150 nM; 24 h) 可呈剂量依赖性抑制小鼠 BV-2 小胶质细胞中 LPS 诱导的 TNF-α 蛋白生成。
(5R)-5-Hydroxytriptolide (50-150 nM; 24 h) 可呈剂量依赖性抑制脂多糖 (LPS) 诱导的小鼠原代小胶质细胞中 NO 的生成,且不会降低细胞活力。
(5R)-5-Hydroxytriptolide (50-150 nM; 12-48 h) 在 150 nM 浓度下可于 48 h 时抑制小鼠 BV-2 小胶质细胞中 LPS 诱导的 iNOS 和 TLR4 蛋白表达,并在 24 h 时呈剂量依赖性抑制 LPS 诱导的 IκBα 磷酸化。
(5R)-5-Hydroxytriptolide (150 nM) 可部分抑制脂多糖 (LPS) 诱导的小鼠 BV-2 小胶质细胞中 NF-κB (p65) 的核转位。
(5R)-5-Hydroxytriptolide (40-400 nM; 24-72 h) 可在体外呈剂量依赖性地抑制亲本 A549 细胞和脑转移性 A549-BrM2 细胞的增殖。
(5R)-5-Hydroxytriptolide (40 nM; 7-14 days) 可降低亲本 A549 细胞和脑转移性 A549-BrM2 细胞的集落形成能力。
(5R)-5-Hydroxytriptolide (24 h) 可调控脑转移性 A549-BrM2 细胞的基因表达,抑制包括 DNA 复制和细胞周期在内的增殖相关通路,且能上调 Tp53,但不会显著诱导其负调控因子 Mdm2。
(5R)-5-Hydroxytriptolide (200-400 nM) 可剂量依赖性调控亲本 A549 细胞和脑转移性 A549-BrM2 细胞中的细胞周期调控蛋白 (Cyclin-B1、Cyclin-D1、p27),从而阻断细胞周期进程。
(5R)-5-Hydroxytriptolide (200-400 nM) 可选择性诱导脑转移性 A549-BrM2 细胞 (而非亲本 A549 细胞) 中 p53 蛋白积累,并调控两种细胞系中凋亡相关蛋白 (BAX、Bcl-2) 的表达以促进细胞凋亡。
(5R)-5-Hydroxytriptolide (200-400 nM; 24 h) 可在体外呈剂量依赖性诱导亲本 A549 细胞和脑转移性 A549-BrM2 细胞发生凋亡,且对 BrM2 细胞的作用更强。
(5R)-5-Hydroxytriptolide 可强效抑制多种体外免疫应答,包括丝裂原诱导的 T、B 细胞增殖、混合淋巴细胞反应以及炎症/Th1 型细胞因子的释放。
(5R)-5-Hydroxytriptolide (12.5-50 nM; 6 day) 可降低 RAW264.7 细胞中 RANKL/M-CSF 诱导的 TRAP 阳性破骨细胞样细胞的形成。
(5R)-5-Hydroxytriptolide (50 nM; 4 h pre-incubation) 可抑制 RAW264.7 细胞中 RANKL 诱导的 IκB 磷酸化,但不抑制 p38、JNK、ERK 或 Akt 的磷酸化。
(5R)-5-Hydroxytriptolide 可在体外抑制伴刀豆球蛋白 A 或 Sac 刺激的小鼠脾细胞中 IFN-γ 的产生。
(5R)-5-Hydroxytriptolide (48 h) 在小鼠脾淋巴细胞中表现出低细胞毒性,孵育 48 h 后的 CC50 为 256.6 nM。
(5R)-5-Hydroxytriptolide (48 h) 可抑制刀豆蛋白 A (ConA) 诱导的小鼠脾淋巴细胞增殖,孵育 48 h 后的 IC50 为 131.7 nM。
(5R)-5-Hydroxytriptolide (孵育 48 h) 可抑制 LPS 诱导的小鼠脾淋巴细胞增殖,孵育 48 h 后的 IC50 为 171.5 nM。
(5R)-5-Hydroxytriptolide (96 h) 可抑制小鼠脾淋巴细胞的混合淋巴细胞反应增殖,总孵育 96 h 后的 IC50 为 38.8 nM。
(5R)-5-Hydroxytriptolide (25-100 nM; 24 h) 可剂量依赖性地降低刀豆蛋白 A (ConA) 诱导的 BALB/c 小鼠脾淋巴细胞中 IL-2、IFN-γ、IL-4 和 IL-6 的产生,实验条件为在 25、50 和 100 nM 浓度下孵育 24 h。
(5R)-5-Hydroxytriptolide (25-100 nM; 24 h) 可剂量依赖性地降低 Sac 诱导的 BALB/c 小鼠脾淋巴细胞中 IFN-γ 和 TNF-α 的产生 (25、50 和 100 nM 浓度下孵育 24 h),但对 IL-12p40 或 IL-10 的产生无影响。

Real Time qPCR

Cell Line: mouse BV-2 microglial cells
Concentration: 50; 100; 150 nM
Incubation Time: 6 h
Result: Dose-dependently inhibited LPS-induced mRNA expression of iNOS, IL-1β, and TNF-α.
Significantly reduced expression at 50 nM.
Caused a greater reduction at 100 nM.
Caused the strongest reduction at 150 nM, with significant differences compared to LPS-only treatment at each concentration.

ELISA Assay

Cell Line: mouse BV-2 microglial cells
Concentration: 50; 100; 150 nM
Incubation Time: 24 h
Result: Dose-dependently reduced LPS-induced TNF-α protein production.
Significantly inhibited TNF-α protein production at 150 nM.

Western Blot Analysis

Cell Line: mouse BV-2 microglial cells
Concentration: 50; 100; 150 nM
Incubation Time: 12 h, 24 h, 48 h
Result: Significantly reduced LPS-induced iNOS protein levels at 48 h at 150 nM.
Reduced LPS-induced TLR4 protein levels at 48 h at 150 nM.
Inhibited LPS-induced p-IκBα levels at 24 h in a dose-dependent manner, with significant inhibition observed at 150 nM.

Western Blot Analysis

Cell Line: Murine RAW264.7 cells
Concentration: 50 nM
Incubation Time: 4 h (pre-incubation); 0, 10, 30, 60 min (RANKL induction)
Result: Markedly inhibited the RANKL-induced increase in phosphorylated IκB (p-IκB) levels across all time points tested.
Showed no significant effects on RANKL-induced phosphorylated p38, JNK, ERK, or Akt levels.

ELISA Assay

Cell Line: BALB/c splenic lymphocytes
Concentration: 25; 50; 100 nM
Incubation Time: 24 h
Result: Dose-dependently reduced ConA-induced production of IL-2, IFN-γ, IL-4, and IL-6.
Dose-dependently reduced Sac-induced production of IFN-γ and TNF-α, but had no apparent effect on IL-12p40 or IL-10 production.
体内研究
(In Vivo)

(5R)-5-Hydroxytriptolide (0.5-1 mg/kg;腹腔注射;再灌注后立即单次给药) 可显著小鼠降低脑梗死体积及促炎细胞因子的表达,对急性脑缺血/再灌注损伤具有保护作用。
(5R)-5-Hydroxytriptolide (1 mg/kg;腹腔注射;每两天一次;共 24 天) 对裸鼠非小细胞肺癌脑转移瘤生长具有抑制效果。
(5R)-5-Hydroxytriptolide (0.5-2 mg/kg;每日给药;持续 1 周) 可以剂量依赖方式减轻大鼠胶原诱导性关节炎。
(5R)-5-Hydroxytriptolide (1 mg/kg/天;口服;每日给药;持续至实验结束) 可在小鼠异基因骨髓移植模型中预防移植物抗宿主病,使大多数接受治疗的小鼠存活期延长至>60 天。
(5R)-5-Hydroxytriptolide (0.5-2 mg/kg;腹腔注射;每日;连续 7 或 14 天) 可呈剂量依赖性地保护小鼠免受博来霉素 (MS-I95244) 诱导的肺纤维化。
(5R)-5-hydroxytriptolide (0.4-1000 μg/kg;腹腔注射、口服;给药两次:攻击前 1 小时和攻击后 12 小时) 可剂量依赖性地抑制 DNFB 诱导的雌性 BALB/c 小鼠迟发型超敏反应,在 1000 μg/kg 口服剂量下可使耳肿胀程度最大降低 43.3%。
(5R)-5-hydroxytriptolide (40-1000 μg/kg;腹腔注射、口服;每日 1 次;连续 4 天) 可剂量依赖性地抑制 BALB/c 小鼠中 SRBC 诱导的体液免疫应答。

Animal Model: ICR mice (male, 25-30 g, middle cerebral artery occlusion with monofilament technique, 1 h occlusion followed by reperfusion)
Dosage: 0.5 mg/kg; 1 mg/kg
Administration: i.p.; single dose immediately post-reperfusion
Result: Significantly reduced infarct volumes in the cortex, striatum, and whole hemisphere (with edema correction) compared to vehicle.
Remarkably attenuated cortical tissue mRNA expression of TNF-α, iNOS, and IL-1β in the ischemic penumbra 24 h after reperfusion.
Animal Model: nude mice (female, 5-6 weeks)
Dosage: 1 mg/kg
Administration: i.p.; every other day; 24 days
Result: Showed a dramatic reduction in tumor radiance compared to vehicle controls by day 45.
Significantly reduced the proportion of Ki67-positive tumor cells compared to vehicle controls.
Significantly down-regulated Ki67 expression intensity compared to vehicle controls.
Caused no obvious weight loss, abnormal behavior, organ weight alterations, or histopathological abnormalities in heart, liver, spleen, lung, or kidney.
Animal Model: Sprague-Dawley (male, weight 260 g)
Dosage: 0.5 mg/kg; 1 mg/kg; 2 mg/kg
Administration: daily; 1 week
Result: Significantly reduced clinical arthritis scores in a dose-dependent manner at 1 mg/kg and 2 mg/kg doses.
Significantly suppressed collagen-induced increases in IL-1β and IL-6 at 1 mg/kg and 2 mg/kg doses.
Reduced iNOS protein expression at 1 mg/kg and 2 mg/kg doses.
Reduced MMP-13 protein expression at 1 mg/kg and 2 mg/kg doses.
Increased OPG gene expression at 1 mg/kg and 2 mg/kg doses.
Decreased RANKL gene expression at 1 mg/kg and 2 mg/kg doses.
Increased the OPG/RANKL ratio at 1 mg/kg and 2 mg/kg doses.
Inhibited RANKL-induced NF-κB expression at 1 mg/kg and 2 mg/kg doses.
Animal Model: C57BL/6 (H-2b) (male, 8 to 10 weeks of age, allo-BMT model with 8.5 Gy total body irradiation prior to intravenous injection of BALB/c bone marrow and splenocytes)
Dosage: 1 mg/kg/day
Administration: p.o.; daily; until end of experiment
Result: Extended survival of majority of treated mice to >60 days, whereas vehicle-treated mice died within 40 days.
Showed inconspicuous weight loss compared to vehicle-treated mice.
Maintained complete/near-complete donor chimerism in splenocytes.
Induced T cell unresponsiveness to donor (H-2d) and host (H-2b) antigens while preserving responsiveness to ConA.
Reduced spontaneous, ConA-stimulated, and host antigen-stimulated IFN-γ levels on day 7 post-transplantation.
Normalized CD4+/CD8+ T cell ratio to 1.16, 1.18, 0.74, and 1.08 on days 7, 14, 21, and 28 post-transplantation, respectively.
Increased Foxp3 mRNA expression in splenocytes on day 14 post-transplantation.
Animal Model: C57BL/6 (female, 6-8 weeks old, 20-22 g, bleomycin-induced lung fibrosis)
Dosage: 0.5 mg/kg; 1 mg/kg; 2 mg/kg
Administration: i.p.; daily; 7 or 14 consecutive days
Result: Dose-dependently attenuated bleomycin-induced body weight loss and inhibited increases in lung index on days 7 and 14.
Markedly reduced lung inflammation and fibrosis on day 14, with no obvious fibrotic foci in the 2 mg/kg group.
Dose-dependently reduced total cells, neutrophils, and lymphocytes in bronchoalveolar lavage fluid.
Reduced lung hydroxyproline levels.
Enhanced lung superoxide dismutase (SOD) activity.
Inhibited lung malondialdehyde production.
Suppressed pro-inflammatory and pro-fibrotic cytokine production.
Dose-dependently reduced transforming growth factor-β (TGF-β) levels, with 2 mg/kg returning TGF-β to near normal control levels on both days 7 and 14.
Animal Model: BALB/c (female, 6 to 8 weeks old, DNFB-sensitized delayed-type hypersensitivity model)
Dosage: 0.4 μg/kg (i.p.); 4 μg/kg (i.p.); 40 μg/kg (i.p., p.o.); 200 μg/kg (p.o.); 1000 μg/kg (p.o.)
Administration: i.p.; two doses (1 h pre-challenge and 12 h post-challenge); p.o.; two doses (1 h pre-challenge and 12 h post-challenge)
Result: Reduced ear swelling to 17.7 mg, 15.3 mg, and 17.1 mg at i.p. doses of 0.4 μg/kg, 4 μg/kg, and 40 μg/kg, respectively.
Reduced ear swelling to 33.8 mg, 30.0 mg, and 24.1 mg at p.o. doses of 40 μg/kg, 200 μg/kg, and 1000 μg/kg, respectively.
Achieved dose-dependent suppression of 20.5%, 29.5%, and 43.3% at p.o. doses of 40 μg/kg, 200 μg/kg, and 1000 μg/kg, respectively.
Animal Model: BALB/c (6 to 8 weeks old, 8 mice per group, SRBC-immunized humoral immune response model)
Dosage: 40 μg/kg (i.p., p.o.); 200 μg/kg (i.p., p.o.); 1000 μg/kg (i.p., p.o.)
Administration: i.p.; daily; 4 days; p.o.; daily; 4 days
Result: Reduced SRBC hemolysis to 0.175 OD, 0.162 OD, and 0.158 OD at i.p. doses of 40 μg/kg, 200 μg/kg, and 1000 μg/kg, respectively.
Suppressed hemolysis by 24.0% at 1000 μg/kg i.p.
Reduced SRBC hemolysis to 0.236 OD, 0.342 OD, and 0.240 OD at p.o. doses of 40 μg/kg, 200 μg/kg, and 1000 μg/kg, respectively.
Suppressed hemolysis by 36.3% at 1000 μg/kg p.o.
性状 固体
颜色 White to off-white

化学信息

分子量 376.40
分子式 C20H24O7
CAS No. 583028-68-6
别名 PG 701; LLDT-8; 5α-Hydroxytriptolide

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础